EDSA Insider Trading

Insider Ownership Percentage: 26.50%
Insider Buying (Last 12 Months): $20,000.00
Insider Selling (Last 12 Months): $0.00

Edesa Biotech Insider Trading History Chart

This chart shows the insider buying and selling history at Edesa Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Edesa Biotech Share Price & Price History

Current Price: $4.48
Price Change: +0.30 (1.20%)
As of 04/12/2024 01:00 AM ET

This chart shows the closing price history over time for EDSA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Edesa Biotech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/25/2024Pardeep NijhawanCEOBuy5,000$4.00$20,000.00341,702View SEC Filing Icon  
1/9/2023Der Velden Peter VanMajor ShareholderSell20,732$18.62$386,029.8423,310View SEC Filing Icon  
6/30/2022Pardeep NijhawanCEOBuy2,857$11.20$31,998.4084,973View SEC Filing Icon  
6/29/2022Michael J. BrooksPresidentBuy428$10.43$4,464.043,748View SEC Filing Icon  
6/16/2022Michael J. BrooksPresidentBuy428$11.27$4,823.563,320View SEC Filing Icon  
5/27/2022Pardeep NijhawanCEOBuy714$13.44$9,596.1682,116View SEC Filing Icon  
5/25/2022Michael J. BrooksPresidentBuy500$12.18$6,090.002,891View SEC Filing Icon  
5/24/2022Pardeep NijhawanCEOBuy285$12.60$3,591.0081,401View SEC Filing Icon  
3/31/2022Pardeep NijhawanCEOBuy285$20.93$5,965.05View SEC Filing Icon  
3/29/2022Pardeep NijhawanCEOBuy285$21.14$6,024.90View SEC Filing Icon  
3/17/2022Pardeep NijhawanCEOBuy285$22.82$6,503.70View SEC Filing Icon  
3/15/2022Pardeep NijhawanCEOBuy285$19.60$5,586.00View SEC Filing Icon  
3/14/2022Michael J. BrooksPresidentBuy178$19.53$3,476.34View SEC Filing Icon  
3/11/2022Pardeep NijhawanCEOBuy1,000$21.63$21,630.00View SEC Filing Icon  
3/10/2022Michael J. BrooksPresidentBuy142$22.54$3,200.68View SEC Filing Icon  
3/9/2022Pardeep NijhawanCEOBuy214$21.35$4,568.90View SEC Filing Icon  
3/8/2022Michael J. BrooksPresidentBuy178$20.30$3,613.40View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Edesa Biotech (NASDAQ:EDSA)

5.50% of Edesa Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at EDSA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Edesa Biotech Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
3/11/2024Vanguard Group Inc.16,345$75K0.0%-85.3%0.516%Search for SEC Filing on Google Icon
2/15/2024Vanguard Group Inc.16,345$75K0.0%-85.3%0.516%Search for SEC Filing on Google Icon
2/7/2024Dimensional Fund Advisors LP11,333$52K0.0%N/A0.359%Search for SEC Filing on Google Icon
11/7/2023CM Management LLC417,602$0.26M0.3%+11.4%13.874%Search for SEC Filing on Google Icon
8/11/2023Cibc World Market Inc.54,626$44K0.0%N/A0.265%Search for SEC Filing on Google Icon
8/4/2023CM Management LLC375,000$0.30M0.3%+15.4%1.821%Search for SEC Filing on Google Icon
5/8/2023CM Management LLC325,000$0.30M0.4%+3.9%1.620%Search for SEC Filing on Google Icon
2/14/2023Susquehanna International Group LLP15,211$33K0.0%N/A0.079%Search for SEC Filing on Google Icon
2/9/2023CM Management LLC312,773$0.68M0.8%+25.1%1.616%Search for SEC Filing on Google Icon
2/7/2023Lynwood Capital Management Inc.121,845$0.26M0.3%N/A0.630%Search for SEC Filing on Google Icon
11/4/2022CM Management LLC250,000$0.23M0.3%N/A1.617%Search for SEC Filing on Google Icon
8/15/2022Millennium Management LLC53,762$86K0.0%N/A0.348%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC46,248$74K0.0%-44.1%0.299%Search for SEC Filing on Google Icon
8/8/2022Merit Financial Group LLC20,409$33K0.0%N/A0.132%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC82,800$0.25M0.0%+150.2%0.595%Search for SEC Filing on Google Icon
5/5/2022National Bank of Canada FI10,000$30K0.0%+1,518.1%0.072%Search for SEC Filing on Google Icon
11/16/2021Verition Fund Management LLC13,502$100K0.0%N/A0.102%Search for SEC Filing on Google Icon
10/28/2021180 Wealth Advisors LLC20,000$0.16M0.0%+33.3%0.151%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC18,938$100K0.0%+17.4%0.143%Search for SEC Filing on Google Icon
8/13/2021180 Wealth Advisors LLC15,000$70K0.0%N/A0.113%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC74,032$0.39M0.0%+153.3%0.558%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.109,158$0.58M0.0%+88.9%0.823%Search for SEC Filing on Google Icon
5/19/2021Virtu Financial LLC16,138$87K0.0%N/A0.122%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp15,349$83K0.0%N/A0.116%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC29,229$0.16M0.0%N/A0.222%Search for SEC Filing on Google Icon
2/10/2021Renaissance Technologies LLC74,100$0.32M0.0%N/A0.704%Search for SEC Filing on Google Icon
1/19/2021FNY Investment Advisers LLC75,000$0.32M0.1%-37.7%0.713%Search for SEC Filing on Google Icon
10/9/2020FNY Investment Advisers LLC120,407$0.97M0.4%N/A1.279%Search for SEC Filing on Google Icon
2/13/2020Renaissance Technologies LLC25,073$0.10M0.0%+59.2%0.334%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Edesa Biotech logo
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Read More on Edesa Biotech

Today's Range

Now: $4.48
Low: $4.33
High: $4.48

50 Day Range

MA: $4.68
Low: $4.06
High: $5.67

52 Week Range

Now: $4.48
Low: $2.46
High: $8.61

Volume

5,805 shs

Average Volume

8,484 shs

Market Capitalization

$14.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Who are the company insiders with the largest holdings of Edesa Biotech?

Edesa Biotech's top insider shareholders include:
  1. Pardeep Nijhawan (CEO)
  2. Der Velden Peter Van (Major Shareholder)
  3. Michael J Brooks (President)
Learn More about top insider investors at Edesa Biotech.